London: An international research team has identified a new line of bacteria that flavours some of the world's most exclusive cheese.

The age-old tradition dates back at least 8,000 years, but it seems we still have much to learn about the bacteria responsible for turning milk into cheese.

They used DNA fingerprinting techniques to identify eight previously undiscovered microbes on the French cheese Reblochon. Reblochon - a soft, creamy, brie-like cheese - is made in the Savoy mountain region of France.

The team have named the microbes Mycetocola reblochoni after the cheese they were first discovered in.

One of France's great mountain cheeses, Reblochon is a 'smear-ripened' cheese where its surface is washed with a salt solution containing bacteria. This process helps to spread the bacteria across the surface of the cheese, ripening it from the outside in.

Other popular smear-ripened cheeses on the Christmas cheeseboard include Port de Salut, Livarot, Taleggio, Limburger and the Irish cheese Gubbeen.

Project lead Michael Goodfellow of Newcastle University said: "It has always been thought the bacteria cheese makers were putting in at the start of the process gave Reblochon its distinctive flavour.

"What our research actually showed was this new group of bacteria - the reblochoni -were responsible for the ripening process, influencing the taste, texture and smell of the cheese."

Using samples from three different farmhouses, the team carried out a series of modern molecular techniques to classify the bacteria.

Traditionally, smear-ripened cheeses such as Reblochon are exposed to a starter culture, a live mixture containing the microbe Brevibacterium linens, to ripen the cheese, said a Newcastle release.

Now the research has shown that a new group of bacterial strains are involved in the later stage of ripening, out-competing the Brevibacterium and providing the flavour.

The reblochoni microbes are part of a large group of bacteria known as the Actinomycetes, many of which are already used in the production of antibiotics to treat diseases such as tuberculosis and diphtheria.

Goodfellow says the next step will be to study the potential benefits of these new microbes.

These findings were published in the International Journal of Systematic and Evolutionary Microbiology. IANS